Entering text into the input field will update the search result below

Premarket analyst action - healthcare

Aug. 14, 2017 8:23 AM ETKALA BIO, Inc. (KALA) StockSTAA, BDSI, KALA, CBUS, ZCORBy: Douglas W. House, SA News Editor17 Comments
  • Kala Pharmaceuticals (NASDAQ:KALA) initiated with Buy rating and $33 (65% upside) price target by Bank of America Merrill Lynch. Initiated with Outperform rating and $46 (130% upside) price target by Wedbush. Shares are up 4% premarket.
  • Egalet (OTC:EGLT) resumed with Overweight rating and $7 (586% upside) price target by Cantor Fitzgerald. Shares up 8% premarket.
  • BioDelivery Sciences (NASDAQ:BDSI) resumed with Overweight rating and $4.50 (53% upside) price target by Cantor Fitzgerald. Shares up 3% premarket.
  • Calyxt (NASDAQ:CLXT) initiated with Outperform rating and $17 (44% upside) price target by Wells Fargo.
  • STAAR Surgical (NASDAQ:STAA) price target raised to $13 (11% upside) by Benchmark citing bullish outlook in Asia and regulatory progress.
  • Source: Bloomberg

Recommended For You

About KALA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
KALA--
KALA BIO, Inc.